Literature DB >> 7508006

Expression of apolipoprotein B epitopes in low density lipoproteins of hemodialyzed patients.

V Reade1, A Tailleux, R Reade, P Harduin, C Cachera, A Tacquet, J C Fruchart, C Fievet.   

Abstract

Serum and isolated low-density lipoprotein (LDL) composition abnormalities were investigated in 20 hemodialyzed patients with chronic renal failure and 15 healthy normolipidemic subjects for comparison. LDL apolipoprotein B (apo B) epitope accessibility was determined by the use of seven monoclonal antibodies (Mabs). These Mabs recognize fragments on the N-terminal part of apo B (Mabs B1, B4), on the middle part (Mab BL7), on the C-terminal (Mabs BA11, BL3), and the two remaining Mabs recognize conformational epitopes of apo B (BL5, DA7). Mab BA11 recognizes a fragment of apo B which interacts with the B/E receptor. In hemodialyzed patients, LDL content of triglycerides (P < 0.001) and apo CIII (P < 0.005) was increased, while cholesteryl esters (P < 0.005) were decreased. The accessibility of BL5 epitopes of LDL apo B was enhanced (P < 0.05), while BA11 epitope expression was decreased (P < 0.01). The conformation of patients' LDL (CRF-LDL) was probably abnormal and seemed to be related to some modification of the lipidic environment. It is important to consider a structural modification as it alters the B/E receptor recognition domain of apo B. These results confirm LDL abnormalities in hemodialyzed patients and suggest a possible modification of the recognition of the LDL by cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7508006     DOI: 10.1038/ki.1993.389

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  2 in total

1.  Fluvastatin (Lescol) treatment of hyperlipidaemia in patients with renal transplants.

Authors:  L Löcsey; L Asztalos; Z Kincses; G Balázs
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

Review 2.  Lipoprotein metabolism in chronic renal insufficiency.

Authors:  Jeffrey M Saland; Henry N Ginsberg
Journal:  Pediatr Nephrol       Date:  2007-03-28       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.